Sanofi GetGoal Programme On Lyxumia(R) (lixisenatide), As An Add-On To Basal Insulin, Shows Significant Positive Phase III Results

Podiatry Arena Sanofi GetGoal Programme On Lyxumia(R) (lixisenatide), As An Add-On To Basal Insulin, Shows Significant Positive Phase III Results

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

Sanofi GetGoal Programme On Lyxumia(R) (lixisenatide), As An Add-On To Basal Insulin, Shows Significant Positive Phase III Results

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

2nd June 2011, 10:10 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 10,247

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 22 Times in 22 Posts

Sanofi GetGoal Programme On Lyxumia(R) (lixisenatide), As An Add-On To Basal Insulin, Shows Significant Positive Phase III Results

Podiatry Arena members do not see these ads

Sanofi announced today that new results from a Phase III study showed that the investigational product Lyxumia® (lixisenatide), when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes without significantly increasing the...

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Switch to Linear Mode Switch to Hybrid Mode Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is On

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
Lorcaserin Phase 3 Clinical Trial In Patients With Type 2 Diabetes Shows Statistically Significant Weight Loss	RSSFeedBot	Latest Diabetes Medicine Research & News	0	10th November 2010 10:30 AM
Positive Top-line Results From Phase III GETGOAL Clinical Trial Using Once-Daily Lixisenatide In Combination With Basal Insulin	RSSFeedBot	Latest Diabetes Medicine Research & News	0	1st October 2010 06:20 AM
Insulin Drug Study Shows Significant Improvements In More Than 52,000 Diabetic Patients	RSSFeedBot	Latest Diabetes Medicine Research & News	0	2nd March 2009 10:10 AM
CrystalGenomics Announces Positive Phase IIa Results For Osteoarthritis Study Of CG100649	RSSFeedBot	Latest Rheumatology News	0	23rd December 2008 05:30 AM
Non- Steroidal Combination Drug To Treat Psoriasis - Positive Phase 2b Results Showing Efficacy And Synergy DPS-101	RSSFeedBot	Latest Dermatology News	0	4th November 2008 02:21 PM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 04:55 PM.

User Name		Remember Me?
Password